HCM
ALNY icon

Highbridge Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Highbridge Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6,500
Closed -$418K – 1021
2013
Q4 		$418K Buy
6,500
+200
+3% +$11.9K 0.01% 727
2013
Q3 		$403K Buy
+6,300
New +$314K ﹤0.01% 948

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BRC
Blue Ridge Capital New York $215M AUM

Highbridge Capital Management's ALNY Position: Q4 2017 in Review

Highbridge Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2017, closing a stake of 13,656 shares — an estimated $1.6M sold.

Highbridge Capital Management first reported a position in ALNY in Q2 2013 and held it in 8 quarters. The position peaked at $5.64M in Q1 2016. 282 funds tracked by Wall St. Rank hold ALNY as of Q4 2017.

  • Highbridge Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 13,656 Alnylam Pharmaceuticals shares in Q4 2017, an estimated $1.6M.
  • Highbridge Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Highbridge Capital Management's Alnylam Pharmaceuticals position peaked at $5.64M in Q1 2016.
  • 282 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.